In addition to digitalisation, modern medicine is particularly focusing on findings from the field of biotechnology, which, in Dresden, has a lot to offer, including faster, more accurate diagnostic methods and highly accurate treatment options. BIOTEC, the biotechnology centre at the TU Dresden, has been utilising groundbreaking findings to combat diseases for 20 years. The core disciplines currently include dementia research, obtaining findings on the relevance of physical cell properties in the emergence of visual impairments, and the structured recording of medical data to draw conclusions about its effect on other diseases, such as pancreatic cancer. At the Max Bergmann Centre of Biomaterials, biomaterials are developed for various medical disciplines, including dentistry, orthopaedics and regenerative medicine. Meanwhile, live matter is the focus of research at the B CUBE (Centre for Molecular Bioengineering) run by the TU Dresden. Innovative materials and technologies are developed here based on these findings.
And it’s not just in research, but also by serving as the headquarters of international biotech companies, that Dresden has become a global player for innovative medical processes. Its portfolio includes companies such as GSK, ROTOP Pharmaka, Apogepha, Menarini, DewPoint, Lipotype, Gemoab and Riboxx. Biotype, for example, produces and sells molecular diagnostic kits to prove and quantify RNA and DNA markers, making it currently very topical in COVID-19 diagnosis.